These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36640300)

  • 1. A multiplexed in vivo approach to identify driver genes in small cell lung cancer.
    Lee MC; Cai H; Murray CW; Li C; Shue YT; Andrejka L; He AL; Holzem AME; Drainas AP; Ko JH; Coles GL; Kong C; Zhu S; Zhu C; Wang J; van de Rijn M; Petrov DA; Winslow MM; Sage J
    Cell Rep; 2023 Jan; 42(1):111990. PubMed ID: 36640300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.
    Ng SR; Rideout WM; Akama-Garren EH; Bhutkar A; Mercer KL; Schenkel JM; Bronson RT; Jacks T
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):513-521. PubMed ID: 31871154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comprehensive Genomic Analysis for Small Cell Lung Cancer].
    Shibata Y; Udagawa H; Matsumoto S; Goto K
    Gan To Kagaku Ryoho; 2021 Apr; 48(4):476-485. PubMed ID: 33976029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
    Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
    BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically-engineered mouse models of small cell lung cancer: the next generation.
    Oser MG; MacPherson D; Oliver TG; Sage J; Park KS
    Oncogene; 2024 Feb; 43(7):457-469. PubMed ID: 38191672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
    Ciampricotti M; Karakousi T; Richards AL; Quintanal-Villalonga À; Karatza A; Caeser R; Costa EA; Allaj V; Manoj P; Spainhower KB; Kombak FE; Sanchez-Rivera FJ; Jaspers JE; Zavitsanou AM; Maddalo D; Ventura A; Rideout WM; Akama-Garren EH; Jacks T; Donoghue MTA; Sen T; Oliver TG; Poirier JT; Papagiannakopoulos T; Rudin CM
    Cancer Discov; 2021 Dec; 11(12):3214-3229. PubMed ID: 34344693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic profiles of small cell lung cancer.
    George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
    Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
    Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cells Lacking the
    Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
    Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of DHODH as a therapeutic target in small cell lung cancer.
    Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
    Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
    Wang H; Wu S; Li Z; Zhang C; Shang X; Zhao C; Li Z; Lin J; Guo J; Wang Z
    Cancer Sci; 2023 Feb; 114(2):665-679. PubMed ID: 36178064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.